Definitive Contract HHSF223201610105C
Award Date 9/9/16
Potential Completion Date 1/15/18
Potential Value $282K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Yonkers, NY 10710, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
67
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration awarded a $950,450 cost-plus-fixed-fee contract to CFD Research Corporation on June 12, 2023, to develop a computational fluid dynamics and physiologically-based pharmacokinetic (CFD-PBPK) framework for supporting bioequivalence evaluation of ophthalmic drugs. This contract responds to the FDA's Broad Agency Announcement seeking advanced research and development proposals to further regulatory science and innovation, specifically addressing the modernization of...
- This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...
- This is a firm-fixed-price delivery order awarded to We Pharma, Inc., a self-certified small disadvantaged business, by the Food and Drug Administration (FDA) under an Indefinite Delivery Contract (IDC). The purpose of this $399,561.18 award is to provide pharmaceutical drug products to support the FDA's research studies, regulatory activities, and emergency response needs. The contract has an ultimate completion date of August 6, 2024. This delivery order is not set-aside and is part of two...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed-price purchase order to The Pharma Letter LIMITED, a for-profit organization, for a $113,008.00 pharmaceutical subscription for 25 users. The contract has a performance period ending May 20, 2025, with an award date of May 20, 2020. The subscription provides the FDA's Office of Global Policy and Strategy (OGPS) staff with access to global news, expert commentary, and analysis on pharmaceutical, generic,...
- This is a firm fixed-price Blanket Purchase Agreement (BPA) call awarded by the Department of Health and Human Services' Food and Drug Administration (FDA) to McKinsey & Company, Inc. Washington D.C. under the General Services Administration's (GSA) Professional Services Schedule (PSS). The contract is for $5,521,743.66 to provide regulatory modernization services for the FDA's Center for Drug Evaluation and Research (CDER) New Drugs Program. The contract was awarded on September 12, 2018...
- This is a $497,310.00 Firm Fixed Price Definitive Contract awarded by the Food and Drug Administration (FDA), a civilian agency, to Neo-Advent Technologies LLC, a minority-owned, veteran-owned, for-profit limited liability company, for the development of "CRITICAL PROCESS PARAMETERS FOR THE PREPARATION OF AMPHOTERICIN B LIPOSOMES." The contract has no set-aside designation and the ultimate completion date is September 22, 2017. No additional details about larger contract vehicles or...
- This is a $845,852.26 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Certara USA Inc. for the licensing of the company's CDER CERTARA PHOENIX software products. The award is not associated with a set-aside program and is intended to provide the FDA's Office of Clinical Pharmacology with necessary software tools, including Phoenix WinNonlin, NLME, IVIVC, Connect, and Trial Simulator, to support the review of Investigational New Drug (IND), New Drug...
- <p>The Department of Health and Human Services Food and Drug Administration awarded a $175,000.00 firm fixed price purchase order to Cytobioscience, Inc., a for-profit organization, to upgrade the agency's in-house automated patch clamp system. The contract was awarded on September 2, 2018, with a completion date of November 30, 2018. The contract was not set aside for any specific socioeconomic category.</p>
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to R & D Enterprises, Inc., a for-profit small business. The contract, worth $95,980.00, is for the delivery of various scientific instruments and accessories used in bio-processing, research, and testing, such as mass spectrometers, thermal conductivity testers, rheometers, colorimeters, thermomechanical analyzers, and titration calorimeters. The contract has an...
- The Food and Drug Administration awarded a $1.0M firm fixed-price contract to Ita-Suomen Yliopisto (University of Eastern Finland) on September 29, 2023, to conduct research on understanding preservative effects on bioequivalence of topical ocular products. The contract, which extends through November 30, 2026, was awarded under the FDA's Broad Agency Announcement for Advanced Research and Development of Regulatory Science. This research effort supports the FDA's mission to modernize product...